Clinical trials: Adenocarcinoma, open to volunteers
Pancreas Cancer, Pancreas Neoplasm
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
This study aims to assess overall survival, quality of life and resection rates in locally advanced pancreatic cancer
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Disease, Pancreas Adenocarcinoma
- Trial name
- SQUARE (NCT05356039)
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Umeå University
Pancreatic Ductal Adenocarcinoma
Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer
The goal of this clinical trial is to compare the overall survival of thermal ablation combined with chemotherapy and chemotherapy alone in the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC)…
- Trial name
- HOPE-1 (NCT05611359)
- Testing
- Thermal Ablation, Chemotherapy
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Proximal Gastric Adenocarcinoma, Reconstruction
A Prospective Observation Registry Study on the Alimentary Reconstruction After Radical Proximal Gastrectomy
This study is designed as a prospective, real world registry study that compare the safety and efficacy of the different construction methods after radical proximal gastrectomy.
- Trial name
- STAR-PG01 (NCT05539105)
- Testing
- Double tract reconstruction, Gastric conduit reconstruction, Other reconstructions
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021[7]-2030[6]), including a multidisciplinary training program…
- Conditions
- Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Non-resectable, Chemotherapy Effect
- Trial name
- PREOPANC-4 (NCT05524090)
- Testing
- Implementation - International best-practice care
- Where
- Netherlands
- Volunteers
- 223 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
- Conditions
- Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
- Trial name
- NCT05503667
- Testing
- Furmonertinib, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Adenocarcinoma of Esophagogastric Junction
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
The purpose of this study was to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric…
- Trial name
- NICLA (NCT05505461)
- Testing
- neoadjuvant Radiation plus SOX and PD-1 antibody
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peking University People's Hospital
Esophageal Cancer, Esophageal Adenocarcinoma
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Despite treatment according to the CROSS-regimen, median overall survival is less than four years (2.3 QALYs). The burden of disease is within the highest category (0.71 to 1.0).
- Trial name
- TRAP-2 (NCT05188313)
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- Netherlands
- Volunteers
- 376 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Adenocarcinoma
RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).
BACKGROUND: For patients with esophageal cancer, radical esophagectomy with 2-field lymphadenectomy is the cornerstone of the multimodality treatment with curative intent.
- Trial name
- ROBOT-2 (NCT04306458)
- Testing
- Minimally invasive esophagectomy, daVinci Xi system
- Where
- Germany
- Volunteers
- 218 people
- Sponsor
- University Medical Center Mainz
Pancreatic Adenocarcinoma
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
- Trial name
- NCT05268692
- Testing
- GS, GnP
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Kochi University
Pancreatic Ductal Adenocarcinoma
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic…
- Trial name
- NCT04969731
- Testing
- Immuncell-LC, Gemcitabine
- Where
- South Korea
- Volunteers
- 408 people
- Sponsor
- GC Cell Corporation
Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate
PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
This observational study was designed to evaluate progression free survival after PSMA-PET/CT based salvage approach for patients affected by biochemical relapse after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate, Prostate Adenocarcinoma, Prostate Cancer Recurrent
- Trial name
- PSICHE (NCT05022914)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
For locally advanced adenocarcinoma of esophagogastric junction(AEG) (cT3-4aN+M0), neoadjuvant chemotherapy was improved to downstage T and N stage, increase the resectability of tumor, and finally improve the long-term survival.
- Trial name
- NCT04989985
- Testing
- Oxaliplatin+S-1, Sinitilimab+oxaliplatin+S-1
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Prostate Cancer, Prostate Adenocarcinoma
Active Surveillance for Low Risk Prostate Cancer
An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic…
- Trial name
- NCT04146077
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Gastric Cancer, Neoadjuvant Chemotherapy
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
- Trial name
- NCT04384601
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Ruijin Hospital
Locally Advanced Gastric Adenocarcinoma
Immune Checkpoint Inhibitor PD-1 Antibody Combined With Chemotherapy in the Perioperative Treatment of Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
The FOLFIRINOX regimen has become the standard treatment regimen for advanced colorectal cancer, advanced pancreatic cancer and postoperative adjuvant treatment for pancreatic cancer.
- Trial name
- NCT04908566
- Testing
- PD-1 antibody combined with FOLFIRINOX regimen, PD-1 antibody combined with SOX program
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Adenocarcinoma
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
feasibility of using a diffusion sequence of a MRgRT system as an early marker of treatment response during nRCT of rectal adenocarcinoma.
- Trial name
- DWI_RECT_MRGRT (NCT03961776)
- Testing
- MRI-guided radiotherapy by on-board DWI sequences
- Where
- 2 sites in United States, France
- Volunteers
- 39 people
- Sponsor
- Institut Paoli-Calmettes
Pancreas Adenocarcinoma, Pancreas Cancer
PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma
- Trial name
- PaCaReg (NCT04099134)
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- University of Ulm
Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.
- Conditions
- Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment, Histological Type of Neoplasm
- Trial name
- NCT03351842
- Testing
- cis Platinum/Carboplatin, Pemetrexed Disodium, Undergo surgery
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China